LONDON–(BUSINESS WIRE)–#GastrointestinalDiseasesTherapeuticsMarket–Technavio has been monitoring the gastrointestinal diseases therapeutics market and it is poised to grow by USD 22.82 billion during 2020-2024, progressing at a CAGR of almost 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA are some of the major market participants. The increasing incidence of gastrointestinal diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing incidence of gastrointestinal diseases has been instrumental in driving the growth of the market.

Gastrointestinal Diseases Therapeutics Market 2020-2024: Segmentation

Gastrointestinal Diseases Therapeutics Market is segmented as below:

• Drug Class
  • Anti-inflammatory and Immunosuppressors
  • Acid Neutralizers
  • Other Therapeutics
• Geography
  • North America
  • Europe
  • Asia
  • ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43343

Gastrointestinal Diseases Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our gastrointestinal diseases therapeutics market report covers the following areas:

• Gastrointestinal Diseases Therapeutics Market Size
• Gastrointestinal Diseases Therapeutics Market Trends
• Gastrointestinal Diseases Therapeutics Market Industry Analysis

This study identifies strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years.

Gastrointestinal Diseases Therapeutics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the gastrointestinal diseases therapeutics market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA Backed with competitive intelligence and benchmarking, our research reports on the gastrointestinal diseases therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Gastrointestinal Diseases Therapeutics Market 2020-2024: Key Highlights

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will assist gastrointestinal diseases therapeutics market growth during the next five years
• Estimation of the gastrointestinal diseases therapeutics market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the gastrointestinal diseases therapeutics market
• Analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of gastrointestinal diseases therapeutics market vendors

Table Of Contents:

Executive Summary

Market Landscape

• Market ecosystem
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2019
• Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

• Five forces summary
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Drug class

• Market segments
• Comparison by Drug class
• Anti-inflammatory and immunosuppressors – Market size and forecast 2019-2024
• Acid neutralizers – Market size and forecast 2019-2024
• Other therapeutics – Market size and forecast 2019-2024
• Market opportunity by Drug class

Customer Landscape

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Overview
• Vendor landscape
• Landscape disruption
• Industry risks

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co. Inc.
• Takeda Pharmaceutical Co. Ltd.
• UCB SA

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: www.technavio.com/

LONDON–(BUSINESS WIRE)–#GastrointestinalDiseasesTherapeuticsMarket–Technavio has been monitoring the gastrointestinal diseases therapeutics market and it is poised to grow by USD 22.82 billion during 2020-2024, progressing at a CAGR of almost 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA are some of the major market participants. The increasing incidence of gastrointestinal diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing incidence of gastrointestinal diseases has been instrumental in driving the growth of the market.

Gastrointestinal Diseases Therapeutics Market 2020-2024: Segmentation

Gastrointestinal Diseases Therapeutics Market is segmented as below:

• Drug Class
  • Anti-inflammatory and Immunosuppressors
  • Acid Neutralizers
  • Other Therapeutics
• Geography
  • North America
  • Europe
  • Asia
  • ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43343

Gastrointestinal Diseases Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our gastrointestinal diseases therapeutics market report covers the following areas:

• Gastrointestinal Diseases Therapeutics Market Size
• Gastrointestinal Diseases Therapeutics Market Trends
• Gastrointestinal Diseases Therapeutics Market Industry Analysis

This study identifies strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years.

Gastrointestinal Diseases Therapeutics Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the gastrointestinal diseases therapeutics market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA Backed with competitive intelligence and benchmarking, our research reports on the gastrointestinal diseases therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Gastrointestinal Diseases Therapeutics Market 2020-2024: Key Highlights

• CAGR of the market during the forecast period 2020-2024
• Detailed information on factors that will assist gastrointestinal diseases therapeutics market growth during the next five years
• Estimation of the gastrointestinal diseases therapeutics market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the gastrointestinal diseases therapeutics market
• Analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of gastrointestinal diseases therapeutics market vendors

Table Of Contents:

Executive Summary

Market Landscape

• Market ecosystem
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2019
• Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

• Five forces summary
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Drug class

• Market segments
• Comparison by Drug class
• Anti-inflammatory and immunosuppressors – Market size and forecast 2019-2024
• Acid neutralizers – Market size and forecast 2019-2024
• Other therapeutics – Market size and forecast 2019-2024
• Market opportunity by Drug class

Customer Landscape

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Overview
• Vendor landscape
• Landscape disruption
• Industry risks

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co. Inc.
• Takeda Pharmaceutical Co. Ltd.
• UCB SA

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: www.technavio.com/